Cargando…

Colesevelam ameliorates non-alcoholic steatohepatitis and obesity in mice

BACKGROUND: Obesity, non-alcoholic fatty liver disease (NAFLD) and its more advanced form non-alcoholic steatohepatitis (NASH) are important causes of morbidity and mortality worldwide. Bile acid dysregulation is a pivotal part in their pathogenesis. The aim of this study was to evaluate the bile ac...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hartmann, Phillipp, Duan, Yi, Miyamoto, Yukiko, Demir, Münevver, Lang, Sonja, Hasa, Elda, Stern, Patrick, Yamashita, Dennis, Conrad, Mary, Eckmann, Lars, Schnabl, Bernd
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer India 2022
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9013343/ https://www.ncbi.nlm.nih.gov/pubmed/35075592 http://dx.doi.org/10.1007/s12072-022-10296-w

Ejemplares similares

Colesevelam Reduces Ethanol-Induced Liver Steatosis in Humanized Gnotobiotic Mice
por: Cabré, Noemí, et al.
Publicado: (2021)

Effect of Colesevelam on Liver Fat Quantified by Magnetic Resonance in Nonalcoholic Steatohepatitis: A Randomized Controlled Trial
por: Le, Thuy-Anh, et al.
Publicado: (2012)

The intestinal microbiome and the leaky gut as therapeutic targets in alcoholic liver disease
por: Hartmann, Phillipp, et al.
Publicado: (2012)

Role of Colesevelam in Combination Lipid-Lowering Therapy
por: Jones, Michael R., et al.
Publicado: (2013)

Inexpensive, Accurate, and Stable Method to Quantitate Blood Alanine Aminotransferase (ALT) Levels
por: Hartmann, Phillipp, et al.
Publicado: (2022)

Dynamic Changes of the Fungal Microbiome in Alcohol Use Disorder
por: Hartmann, Phillipp, et al.
Publicado: (2021)

Safety and Efficacy of Colesevelam HCl in the Treatment of Elderly Patients
por: Gavin, James R., et al.
Publicado: (2014)

Intestinal virome in patients with alcohol use disorder and after abstinence
por: Hsu, Cynthia L., et al.
Publicado: (2022)

Lamin Deficiency in the Liver Sets the Stage for Nonalcoholic Steatohepatitis Development in Males
por: Hendrikx, Tim, et al.
Publicado: (2017)

Nonalcoholic Steatohepatitis Disrupts Diurnal Liver Transcriptome Rhythms in Mice
por: de Assis, Leonardo Vinicius Monteiro, et al.
Publicado: (2023)

Role of colesevelam in managing heterozygous familial hypercholesterolemia in adolescents and children
por: Sonnett, Travis, et al.
Publicado: (2010)

Malassezia restricta promotes alcohol-induced liver injury
por: Zeng, Suling, et al.
Publicado: (2023)

Colesevelam hydrochloride: reducing atherosclerotic coronary heart disease risk factors
por: Bays, Harold, et al.
Publicado: (2007)

Colesevelam hydrochloride: A novel agent in patients with type 2 diabetes
por: Sekhri, Kavita, et al.
Publicado: (2011)

Atypical Mechanism of Glucose Modulation by Colesevelam in Patients with Type 2 Diabetes
por: Nwose, Oliseyenum M., et al.
Publicado: (2013)

Effectiveness and Tolerability of Colesevelam HCl for Accelerated Elimination of Teriflunomide in Healthy Participants
por: Lunven, Catherine, et al.
Publicado: (2017)

Colesevelam‐induced hypoglycaemia in a patient with type 1 diabetes mellitus
por: Pavlou, Panagiotis, et al.
Publicado: (2021)

The analysis of gut microbiota in patients with bile acid diarrhoea treated with colesevelam
por: Kumar, Aditi, et al.
Publicado: (2023)

Global and national prevalence of nonalcoholic fatty liver disease in adolescents: An analysis of the global burden of disease study 2019
por: Hartmann, Phillipp, et al.
Publicado: (2023)

Colesevelam lowers glucose and lipid levels in type 2 diabetes: the clinical evidence
por: Fonseca, Vivian A, et al.
Publicado: (2010)

Effect of Colesevelam HCl Monotherapy on Lipid Particles in Type 2 Diabetes Mellitus
por: Rosenson, Robert S., et al.
Publicado: (2014)

Colesevelam enhances the beneficial effects of brown fat activation on hyperlipidaemia and atherosclerosis development
por: Zhou, Enchen, et al.
Publicado: (2020)

Tumor necrosis factor alpha receptor 1 deficiency in hepatocytes does not protect from non-alcoholic steatohepatitis, but attenuates insulin resistance in mice
por: Bluemel, Sena, et al.
Publicado: (2020)

Real-world utilization patterns and outcomes of colesevelam hcl in the ge electronic medical record
por: Hansen, Richard A, et al.
Publicado: (2013)

Management of Dyslipidemia in Patients with Non-Alcoholic Fatty Liver Disease
por: Martin, Anna, et al.
Publicado: (2022)

Changes in the fecal bacterial microbiota associated with disease severity in alcoholic hepatitis patients
por: Lang, Sonja, et al.
Publicado: (2020)

Berberine ameliorates non-alcoholic steatohepatitis in ApoE(−/−) mice
por: Yang, Jin, et al.
Publicado: (2017)

Improving glycemic and cholesterol control through an integrated approach incorporating colesevelam – a clinical perspective
por: Goldberg, Ronald B
Publicado: (2009)

β-glycosphingolipids ameliorated non-alcoholic steatohepatitis in the Psammomys obesus model
por: Zigmond, Ehud, et al.
Publicado: (2014)

Chymase as a Possible Therapeutic Target for Amelioration of Non-Alcoholic Steatohepatitis
por: Takai, Shinji, et al.
Publicado: (2020)

GPx7 ameliorates non-alcoholic steatohepatitis by regulating oxidative stress
por: Kim, Hyeon Ju, et al.
Publicado: (2020)

Colesevelam Improves Oral but Not Intravenous Glucose Tolerance by a Mechanism Independent of Insulin Sensitivity and β-Cell Function
por: Marina, Anna L., et al.
Publicado: (2012)

Colesevelam hydrochloride: evidence for its use in the treatment of hypercholesterolemia and type 2 diabetes mellitus with insights into mechanism of action
por: Zema, Michael James
Publicado: (2012)

Drug Development Against the Major Diarrhea-Causing Parasites of the Small Intestine, Cryptosporidium and Giardia
por: Miyamoto, Yukiko, et al.
Publicado: (2015)

Artemether Ameliorates Non-Alcoholic Steatohepatitis by Repressing Lipogenesis, Inflammation, and Fibrosis in Mice
por: Xu, Jia, et al.
Publicado: (2022)

Targeting acid ceramidase ameliorates fibrosis in mouse models of non-alcoholic steatohepatitis
por: Yu, Amy, et al.
Publicado: (2022)

Functional Microbial Responses to Alcohol Abstinence in Patients With Alcohol Use Disorder
por: Gao, Bei, et al.
Publicado: (2020)

The Role of Intestinal C‐type Regenerating Islet Derived‐3 Lectins for Nonalcoholic Steatohepatitis
por: Bluemel, Sena, et al.
Publicado: (2018)

Lysosomal-associated protein transmembrane 5 ameliorates non-alcoholic steatohepatitis by promoting the degradation of CDC42 in mice
por: Jiang, Lang, et al.
Publicado: (2023)

Machine Learning Applied to Omics Datasets Predicts Mortality in Patients with Alcoholic Hepatitis
por: Gao, Bei, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_m4lffofdre8oocjpf4p8tjlci3